Pfizer: Coming Clean on Lipitor

Seems Pfizer admitted to the SEC that its superiority data regarding Lipitor (atorvastatin) over Zocor (simvastatin) was overstated. They might have the same efficacy rate. It seems they were forced to reconsider their claims:

The error was discovered while researchers were re-analyzing the data at the request of an expert who was reviewing the manuscript, which had been submitted for publication in a journal. (Pfizer senior vice president Michael) Berelowitz declined to name the publication.

Hmmm. I'm intrigued. There must me something going on here. Why would Pfizer suddenly decide to come clean and surrender their profits to generic simvastatin? Could people be on to their techniques?

-Wes

Reference: Wall Street Journal's Health Blog